Architecture & IP 

APX: Modular, Agentic, Causal Architecture for Multimodal Biomedical Intelligence

1. Vision

APX is a modular, agentic, causal AI architecture built to transform multimodal biomedical data into interpretable biomarkers, therapeutic insights, and disease aware reasoning. It uses a deterministic, forward only DAG to orchestrate specialized modules governed by transparent rules, provenance, and evaluator logic. The platform is disease agnostic, modality agnostic, and scalable across therapeutic areas, enabling enterprise grade reproducibility and regulatory alignment.

2. Core Architectural Principles

Modular DAG Structure

• Fixed, acyclic, forward only pipeline

• Stateless modules; immutable objects; deterministic execution

• Each module encapsulates a well defined computational responsibility

Agentic Mini Controllers

• Each module contains a mini controller orchestrating internal sub agents

• Sub agents handle multimodal tasks (omics, imaging, spatial, clinical, text)

• Controllers enforce rules, evaluator checks, and provenance capture

Causal Reasoning Layer

• Integrates causal graphs, mechanistic priors, and biological constraints

• Produces explainable, intervention aware outputs

• Supports counterfactual reasoning and biomarker robustness scoring

Healthy Baseline Engine

• Learns organ  and modality specific healthy reference distributions

• Enables deviation scoring and early biomarker detection

• Forms the foundation for disease aware inference

Biomarker Extraction Logic (BEL)

• Formalized, rule driven system for identifying and ranking biomarkers

• Integrates multimodal evidence, causal signals, and robustness indicators

• Produces structured, audit ready biomarker candidates

3. Key Capabilities

• Multimodal fusion across omics, imaging, spatial, EHR, and text

• Agentic orchestration for complex biomedical workflows

• Causal inference for mechanistic interpretability and regulatory trust

• Reusable modules for rapid adaptation to new diseases or datasets

• Provenance rich outputs suitable for clinical validation

• Scalable deployment across pharma, biotech, and clinical research

4. Applications

• Biomarker discovery & validation

• Disease progression modeling

• Therapeutic response prediction

• Toxicity & safety signal detection

• Clinical trial enrichment

• Multimodal patient stratification

• Digital pathology & spatial biology integration

5. IP & Commercialization

• Multiple USPTO provisional filings covering architecture, BEL logic, healthy baseline modeling, and agentic orchestration

• Designed for licensing, co development, enterprise deployment, and strategic partnerships

6. Collaboration Opportunities

APX is seeking:

• Strategic partnerships with pharma/biotech for clinical validation pilots

• Co development collaborations with AI platform teams

• Enterprise adoption for multimodal biomarker programs

• Advisory or leadership roles within organizations building next generation biomedical AI systems